Trending Topic

14 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Kate Clair Cruden Hughes, Amy Hai Yan Chan

Asthma affects nearly 300 million people worldwide.1 Despite a notable decline in age-standardized prevalence, mortality and disability-adjusted life years over the past three decades, the burden of asthma remains high in many countries including low-middle-income countries.2 Climate change is also predicted to significantly impact asthma and other respiratory-related conditions, as rising global temperatures lead to longer pollen […]

Lavinia Davidescu, EAACI Digital Congress 2020 – Masitinib for Severe Persistent Asthma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 6th 2020

Following an excellent presentation at the EAACI Digital Congress 2020, we caught up with Lavinia Davidescu (University of Oradea, Romania). We discussed the findings from the phase 3 study of masitinib in the treatment of patients with severe persistent asthma (NCT01449162) and what the future holds.

Questions
1. Could you tell us a little about masitinib and its mechanism of action? (0:04)
2. Could you give us an overview of Study AB07015 and its major efficacy and safety findings? (1:24)
3. What were the findings of the subgroup analysis in eosoniphilic asthma patients, and what are the implications of these findings? (04:29)
4. What future studies are planned? (11:26)

Speaker disclosure: Lavinia Davidescu is the coordinating investigator of masitinib study AB07015 in severe asthma uncontrolled with oral corticosteroids.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of the EAACI Digital Congress 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup